Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Alpine Immune Sciences stock | $10.94

Learn how to easily invest in Alpine Immune Sciences stock.

Alpine Immune Sciences Inc is a biotechnology business based in the US. Alpine Immune Sciences shares (ALPN) are listed on the NASDAQ and all prices are listed in US Dollars. Alpine Immune Sciences employs 57 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Alpine Immune Sciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALPN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Alpine Immune Sciences stock price (NASDAQ: ALPN)

Use our graph to track the performance of ALPN stocks over time.

Alpine Immune Sciences shares at a glance

Information last updated 2021-10-23.
Latest market close$10.94
52-week range$7.21 - $16.37
50-day moving average $10.68
200-day moving average $10.18
Wall St. target price$20.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.46

Buy Alpine Immune Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Alpine Immune Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alpine Immune Sciences price performance over time

Historical closes compared with the close of $10.94 from 2021-10-25

1 week (2021-10-15) N/A
1 month (2021-09-24) 5.60%
3 months (2021-07-26) 29.62%
6 months (2021-04-26) -12.90%
1 year (2020-10-26) 42.63%
2 years (2019-10-25) 287.94%
3 years (2018-10-26) 120.12%
5 years (2016-10-26) 78.76%

Alpine Immune Sciences financials

Revenue TTM $18 million
Gross profit TTM $-17,850,000
Return on assets TTM -16.5%
Return on equity TTM -113.73%
Profit margin -190.22%
Book value $1.83
Market capitalisation $308.1 million

TTM: trailing 12 months

Shorting Alpine Immune Sciences shares

There are currently 474,175 Alpine Immune Sciences shares held short by investors – that's known as Alpine Immune Sciences's "short interest". This figure is 27.6% down from 654,829 last month.

There are a few different ways that this level of interest in shorting Alpine Immune Sciences shares can be evaluated.

Alpine Immune Sciences's "short interest ratio" (SIR)

Alpine Immune Sciences's "short interest ratio" (SIR) is the quantity of Alpine Immune Sciences shares currently shorted divided by the average quantity of Alpine Immune Sciences shares traded daily (recently around 144565.54878049). Alpine Immune Sciences's SIR currently stands at 3.28. In other words for every 100,000 Alpine Immune Sciences shares traded daily on the market, roughly 3280 shares are currently held short.

However Alpine Immune Sciences's short interest can also be evaluated against the total number of Alpine Immune Sciences shares, or, against the total number of tradable Alpine Immune Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alpine Immune Sciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Alpine Immune Sciences shares in existence, roughly 20 shares are currently held short) or 0.0309% of the tradable shares (for every 100,000 tradable Alpine Immune Sciences shares, roughly 31 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alpine Immune Sciences.

Find out more about how you can short Alpine Immune Sciences stock.

Alpine Immune Sciences share dividends

We're not expecting Alpine Immune Sciences to pay a dividend over the next 12 months.

Have Alpine Immune Sciences's shares ever split?

Alpine Immune Sciences's shares were split on a 1:4 basis on 24 July 2017. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alpine Immune Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Alpine Immune Sciences shares which in turn could have impacted Alpine Immune Sciences's share price.

Alpine Immune Sciences share price volatility

Over the last 12 months, Alpine Immune Sciences's shares have ranged in value from as little as $7.21 up to $16.37. A popular way to gauge a stock's volatility is its "beta".

ALPN.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alpine Immune Sciences's is 1.621. This would suggest that Alpine Immune Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Alpine Immune Sciences overview

Alpine Immune Sciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington. .

Frequently asked questions

What percentage of Alpine Immune Sciences is owned by insiders or institutions?
Currently 32.446% of Alpine Immune Sciences shares are held by insiders and 61.865% by institutions.
How many people work for Alpine Immune Sciences?
Latest data suggests 57 work at Alpine Immune Sciences.
When does the fiscal year end for Alpine Immune Sciences?
Alpine Immune Sciences's fiscal year ends in December.
Where is Alpine Immune Sciences based?
Alpine Immune Sciences's address is: 188 East Blaine Street, Seattle, WA, United States, 98102
What is Alpine Immune Sciences's ISIN number?
Alpine Immune Sciences's international securities identification number is: US02083G1004
What is Alpine Immune Sciences's CUSIP number?
Alpine Immune Sciences's Committee on Uniform Securities Identification Procedures number is: 02083G100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site